TECH — BIO-TECHNE Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 842023 ·
Last close
$72.63
Market Cap
$11.41B
52W High
$72.86
52W Low
$43.03
ADV30
3,044,004
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 299,712,000 | 196,623,000 | 36,603,000 | 28,293,000 | 2,636,820,000 | 350,036,000 | 471,131,000 |
| Jun 2026 | 321,192,000 | 211,394,000 | 94,997,000 | 54,621,000 | 2,586,726,000 | 264,712,000 | 478,505,000 |
| Mar 2026 | 311,415,000 | 208,288,000 | 75,495,000 | 51,047,000 | 2,550,601,000 | 209,819,000 | 465,297,000 |
| Dec 2025 | 295,877,000 | 191,277,000 | 54,461,000 | 38,009,000 | 2,522,699,000 | 172,879,000 | 511,710,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$292,073,000
Investing CF
$-18,190,000
Financing CF
$-169,114,000
CapEx
$-28,850,000
Dividends Paid
$-49,916,000
Buybacks
$-41,675,000
EPS Diluted TTM
$1.15
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$1,144,188,000
Inventory
$195,744,000
Receivables
$216,585,000
ST Investments
$0
EBIT TTM
$250,310,000
Pretax Income TTM
$240,680,000
Interest Exp TTM
$9,630,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,228,195,968
EBITDA
$322,436,992
Free Cash Flow
$272,623,744
Enterprise Value
$11,368,582,144
Total Cash
$350,036,000
Total Debt
$285,555,008
Shares Out
157,055,564
Trailing EPS
$1.16
Book Value
$13.79
ROE
8.3%
ROA
6.4%
Div Yield
0.44%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,215,039,000 | 272,611,000 | 181,862,000 | 2,586,726,000 | 478,505,000 | 2,108,221,000 | 292,073,000 |
| Jun 2025 | 1,219,635,000 | 242,804,000 | 73,400,000 | 2,557,868,000 | 639,060,000 | 1,918,808,000 | 287,556,000 |
| Jun 2024 | 1,159,060,000 | 246,401,000 | 168,105,000 | 2,703,867,000 | 635,017,000 | 2,068,850,000 | 298,981,000 |
| Jun 2023 | 1,136,702,000 | 290,998,000 | 285,263,000 | 2,638,692,000 | 672,176,000 | 1,966,516,000 | 254,393,000 |
TTM Snapshot
Revenues TTM
$1,215,039,000
NetIncome TTM
$181,862,000
OpCashFlow TTM
—
Assets (Latest)
$2,550,601,000
Forward EPS
$2.31
Max Pain — expiry 2027-01-15
max pain strike: $55.00 · spot: $72.75 · call oi: 25,595 · put oi: 949
Expected Move to 2027-01-15:
±$2.66
(3.66%) —
implied range
$70.09 –
$75.41
· ATM straddle on $75.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | $10.94B | $95.97 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
| RGEN | REPLIGEN CORP | $10.30B | $162.18 | — |
| QGEN | QIAGEN N.V. | $10.27B | $49.75 | — |
| PCVX | Vaxcyte, Inc. | $9.40B | $59.40 | — |
News headlines (Yahoo Finance, 1h cache)
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances
2026-11-09 12:50 · Yahoo
Bio-Techne (TECH), What Is Behind The Fresh Attention Now?
2026-11-04 19:10 · Yahoo
BIO-TECHNE DECLARES DIVIDEND
2026-11-04 01:30 · Yahoo
2 high-flying stocks worth your attention and 1 we turn down
2026-11-03 12:13 · Yahoo
Stocks rebound as oil prices sink, Anthropic releases Q3 financials: AlphaCheck
2026-11-02 15:00 · Yahoo
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
2026-11-02 11:44 · Yahoo
Alphabet tumbles, software and cybersecurity stocks sink as earnings disappoint: AlphaCheck
2026-10-29 13:53 · Yahoo
What You Need to Know Ahead of Bio-Techne’s Earnings Release
2026-10-26 14:15 · Yahoo
1 Unpopular Stock That Should Get More Attention and 2 We Question
2026-10-09 14:43 · Yahoo
Bio-Techne opens GMP small molecule facility in Bristol, UK
2026-10-09 11:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.